Critical Covid-19 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRT090 MIFTS: 43	Critical Covid-19 Categories: Infectious diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Critical Covid-19

MalaCards integrated aliases for Critical Covid-19:

Name: Critical Covid-19 ¹¹ ¹⁴

Classifications:

MalaCards categories:
Global: Infectious diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0081012

Sources

Summaries for Critical Covid-19

Disease Ontology: ¹¹ A COVID-19 that is characterized by the criteria for acute respiratory distress syndrome (ARDS), sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy.

MalaCards based summary: Critical Covid-19 is related to non-severe covid-19 and lymphopenia. An important gene associated with Critical Covid-19 is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Crofelemer and Phentolamine have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and heart, and related phenotypes are homeostasis/metabolism and immune system

Sources

Related Diseases for Critical Covid-19

Diseases related to Critical Covid-19 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1016)

#	Related Disease	Score	Top Affiliating Genes
1	non-severe covid-19	31.4	TNF TMPRSS2 SERPINA3 IL6 IL10 CXCL8
2	lymphopenia	30.7	IL7 IL6 IL2 IL10 CCR6
3	adult respiratory distress syndrome	30.5	TNF TMPRSS2 SERPINA3 IL6 IL1B IL10
4	nutritional deficiency disease	30.4	SERPINA3 IL6 CRP CCR6
5	thrombocytopenic purpura, autoimmune	30.3	CD8A CD4 CCR6
6	pulmonary fibrosis	30.3	IL1B CXCL8 CCL3 CCL2
7	autoimmune polyendocrine syndrome type 1	30.2	IFNA1 CD4 CCR6
8	autoimmune polyendocrine syndrome	30.2	IFNA1 CD4 CCR6
9	thrombocytopenia due to platelet alloimmunization	30.2	IL10 CD8A CD4 CCR6
10	eosinophilic pneumonia	30.2	IL2 CXCL8 CCL2
11	scleritis	30.2	TNF CRP CCR6 CCL2
12	post-traumatic stress disorder	30.2	IL6 IL1B CRP
13	disseminated intravascular coagulation	30.2	TNF IL6 IL10 CXCL10 CRP CCL2
14	pericardial effusion	30.1	TNF IL6 CRP CD4 ACE2
15	sleep disorder	30.1	TNF IL6 IL1B IL10 CXCL8 CRP
16	covid-19	30.1	TNF TMPRSS2 IL6 IL2 IL1B IL10
17	anxiety	30.1	TNF IL6 IL1B IL10 CXCL8 CRP
18	myasthenia gravis	30.1	TNF IL6 IL2 IL10
19	chronic kidney disease	30.0	TNF IL6 IL1B CRP CCR6
20	pneumonia	30.0	TNF IL6 IL1B IL10 CXCL8 CXCL10
21	hypereosinophilic syndrome	30.0	IL2 IL10 IFNA1 CXCL8
22	toxic shock syndrome	29.9	TNF IL6 IL2 IL1B IL10 CXCL8
23	disease of mental health	29.9	TNF SERPINA3 IL6 IL1B CRP CD4
24	extrinsic allergic alveolitis	29.9	TNF CXCL8 CD8A CD4 CCR6 CCL3
25	cholangitis	29.9	TNF IL6 IL2 IL10 CXCL8 CRP
26	sclerosing cholangitis	29.9	TNF IL6 IL10 CRP CD8A CD4
27	mucormycosis	29.9	TNF IL6 IL10 CSF3 CRP CD8A
28	pre-eclampsia	29.8	TNF IL6 IL1B IL10 CXCL8 CRP
29	liver disease	29.8	TNF SERPINA3 IL6 IFNA1 CCL2
30	cerebrovascular disease	29.8	TNF SERPINA3 IL6 IL1B CRP CCR6
31	herpes zoster	29.8	IL2 IL10 IFNA1 CD8A CD4 CCR6
32	bronchiectasis	29.8	TNF SERPINA3 IL6 IL1B CXCL8 CRP
33	major depressive disorder	29.8	TNF IL6 IL2 IL1B IL10 CRP
34	pulmonary edema	29.8	TNF IL1B IL10 CXCL8 CSF3 CRP
35	substance abuse	29.7	TNF SERPINA3 IL6 IL1B CRP CD4
36	sleep apnea	29.7	TNF IL6 IL1B IL10 CXCL8 CRP
37	purpura	29.7	TNF IL6 IL2 IL1B IL10 CXCL8
38	myopathy	29.6	TNF SERPINA3 IL6 IL1B CRP CD8A
39	vasculitis	29.5	TNF SERPINA3 IL6 IL1B IL10 CXCL8
40	severe acute respiratory syndrome	29.5	TNF TMPRSS2 IL7 IL6 IL2 IL1B
41	aspergillosis	29.4	TNF IL6 IL1B IL10 CXCL8 CXCL10
42	pulmonary tuberculosis	29.4	TNF IL6 IL2 IL1B IL10 CXCL10
43	kidney disease	29.3	TNF IL6 IL2 IL1B IL10 CXCL8
44	cholangitis, primary sclerosing	29.3	TNF IL6 IL1B IL10 CXCL8 CRP
45	myeloma, multiple	29.3	IL7 IL6 IL2 IL1B IFNA1 CSF3
46	neutropenia	29.2	TNF IL6 IL2 IL1B IL10 IFNA1
47	lung disease	29.2	TNF SERPINA3 IL6 IL1B IL10 CXCL8
48	pulmonary disease, chronic obstructive	29.1	TNF SERPINA3 IL6 IL1B CXCL8 CXCL10
49	myocarditis	29.1	TNF IL6 IL2 IL1B IL10 IFNA1
50	exanthem	29.0	TNF IL6 IL2 IL1B IL10 IFNA1

Graphical network of the top 20 diseases related to Critical Covid-19:

Sources

Symptoms & Phenotypes for Critical Covid-19

GenomeRNAi Phenotypes related to Critical Covid-19 according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.15	ACE2 CCL2 CCL3 CCR6 CD4 CD8A
2	no effect	GR00402-S-2	10.15	CCL2 CCL3 CCR6 CD4 CRP CSF3

MGI Mouse Phenotypes related to Critical Covid-19:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.24	ACE2 CCL2 CCL3 CCR6 CD4 CRP
2	immune system	MP:0005387	10.13	ACE2 CCL2 CCL3 CCR6 CD4 CD8A
3	neoplasm	MP:0002006	10.01	CCL2 IFNB1 IL10 IL1B IL2 IL6
4	cardiovascular system	MP:0005385	10	ACE2 CCL2 CCR6 CRP CXCL10 IL10
5	digestive/alimentary	MP:0005381	9.92	ACE2 CCL2 CCL3 CD4 IL10 IL2
6	hematopoietic system	MP:0005397	9.89	ACE2 CCL2 CCL3 CCR6 CD4 CD8A
7	integument	MP:0010771	9.32	ACE2 CCL2 CD4 CD8A CSF3 IL10

Sources

Drugs & Therapeutics for Critical Covid-19

Drugs for Critical Covid-19 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Crofelemer

Approved

Phase 3

33507-63-0, 148465-45-6

36511 44359816

Phentolamine

Approved

Phase 2, Phase 3

50-60-2

5775

Betamethasone

Approved, Vet_approved

Phase 3

378-44-9

9782

Remdesivir

Approved, Investigational

Phase 3

1809249-37-3

121304016

Sargramostim

Approved, Investigational

Phase 3

123774-72-1

Molgramostim

Investigational

Phase 3

99283-10-0

Neurokinin A

Phase 3

86933-74-6

55582

Adrenergic Antagonists

Phase 2, Phase 3

Adrenergic alpha-Antagonists

Phase 2, Phase 3

Neurotransmitter Agents

Phase 2, Phase 3

Adrenergic Agents

Phase 2, Phase 3

Antihypertensive Agents

Phase 2, Phase 3

Gastrointestinal Agents

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Hormones

Phase 3

Hormone Antagonists

Phase 3

Antiemetics

Phase 3

glucocorticoids

Phase 3

Anti-Inflammatory Agents

Phase 3

Antibodies, Monoclonal

Phase 3

Immunoglobulins

Phase 3

Antibodies

Phase 3

Immunoglobulin G

Phase 3

Cannabidiol

Approved, Investigational

Phase 1, Phase 2

13956-29-1

521372 644019

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

3003 5743

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 2

9005-49-6

22833565 9812414 772

Favipiravir

Approved, Investigational

Phase 2

259793-96-9

492405

Maraviroc

Approved, Investigational

Phase 2

376348-65-1

3002977

Anticonvulsants

Phase 1, Phase 2

Antibiotics, Antitubercular

Phase 2

Antiviral Agents

Phase 2

Anti-Bacterial Agents

Phase 2

Anti-Retroviral Agents

Phase 2

Anti-Infective Agents

Phase 2

Anti-HIV Agents

Phase 2

Carbamide peroxide

Approved

124-43-6

Reviparin

Approved, Investigational

9041-08-1

Prednisolone phosphate

Approved, Vet_approved

302-25-0

Prednisolone acetate

Approved, Vet_approved

52-21-1

Acetylsalicylic acid

Approved, Vet_approved

50-78-2

2244

Prednisolone

Approved, Vet_approved

50-24-8

4894 5755

Xylometazoline

Approved, Investigational

526-36-3

5709

Methylprednisolone hemisuccinate

Approved

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

83-43-2

4159 6741

Prednisolone hemisuccinate

Experimental

2920-86-7

4897

Fibrin fragment D

bilirubin

635-65-4

5280352

Chrysarobin

Calcium heparin

Interventional clinical trials:

(show all 23)

#	Name	Status	NCT ID	Phase	Drugs
1	ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection	Unknown status	NCT04326426	Phase 3	Tradipitant;Placebo
2	ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure	Completed	NCT04311697	Phase 2, Phase 3	Aviptadil by intravenous infusion + standard of care;Normal Saline Infusion + standard of care
3	The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19 - a Post-hoc Analysis of the Blinded, Randomized COVID STEROID 2 Trial	Completed	NCT05195242	Phase 3	Dexamethasone
4	A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia	Active, not recruiting	NCT04351152	Phase 3	Standard of Care
5	A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)	Terminated	NCT04750278	Phase 2, Phase 3	FP-025 100 mg;FP-025 300 mg;Placebo
6	Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma	Terminated	NCT04432103	Phase 3
7	Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease	Completed	NCT04380961	Phase 2	Sirukumab;Placebo
8	A Single-Blind Dose-Ranging Pharmacodynamic Study of Auxora for the Treatment of Patients With Critical COVID-19 Pneumonia	Completed	NCT04661540	Phase 2	CM4620-IE (Injectable Emulsion);Placebo
9	Cannabidiol Treatment for Severe and Critical COVID-19 Pulmonary Infection	Recruiting	NCT04731116	Phase 1, Phase 2	Cannabidiol
10	A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)	Active, not recruiting	NCT04922957	Phase 2	ALLOCETRA-OTS
11	A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Severe and Critical COVID-19 Condition	Active, not recruiting	NCT05501418	Phase 1, Phase 2
12	Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19"	Terminated	NCT04475991	Phase 2	Maraviroc + Currently used therapy;Favipiravir + Currently used therapy;Maraviroc+Favipiravir+CT
13	A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia (CARDEA-Plus)	Withdrawn	NCT05171920	Phase 2	Auxora;Placebo
14	A Randomized, Double-blind, Multicentre 2-arm, Parallel-group, Placebo-controlled Study to Investigate the Efficacy and Safety of Intravenous Imatinib Mesylate in Reducing the Severity of Hypoxemic Respiratory Failure in Patients With Critical COVID-19 Receiving Standard of Care.	Withdrawn	NCT04953052	Phase 2	Imatinib Mesylate;Placebo
15	Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection	Completed	NCT04354610
16	Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF	Completed	NCT04344327
17	Clinical Characteristics and Laboratory Values Affecting Mortality in Critical COVID 19 Patients Followed in the Intensive Care Unit	Completed	NCT04659876
18	Is Anti-Factor Xa Associated With Mortality, Thromboembolism and Bleeding in Patients With Critical COVID-19 Patients on Low-Molecular-Weight Heparin?	Completed	NCT05256524		The effect of LMWH
19	A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	Completed	NCT04898088
20	Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19	Completed	NCT04492501		Tocilizumab;Remdesivir
21	Recovery After Critical Covid-19 Infection	Enrolling by invitation	NCT04864938
22	Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai	Not yet recruiting	NCT05422963
23	ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol	No longer available	NCT04453839		ZYESAMI (aviptadil acetate)

Search NIH Clinical Center for Critical Covid-19

Sources

Genetic Tests for Critical Covid-19

Sources

Anatomical Context for Critical Covid-19

Organs/tissues related to Critical Covid-19:

MalaCards : Lung, Kidney, Heart, Bone Marrow, T Cells, Liver, Neutrophil

Sources

Publications for Critical Covid-19

Articles related to Critical Covid-19:

(show top 50) (show all 1239)

#	Title	Authors	PMID	Year
1	Comparison of risk factors and outcome of patients with and without COVID-19-associated pulmonary aspergillosis from Pakistan: A case-control study. ⁶²	Nasir N...Jabeen K	36111367	2023
2	Treatment of Severe Hypertriglyceridemia With Insulin Infusions in Severe COVID-19: A Case Series. ⁶²	Thomas CM...Louzon PR	33882724	2022
3	Remdesivir use in pregnancy during the SARS-CoV-2 pandemic. ⁶²	Gutierrez R...Chauhan SP	35168447	2022
4	Corticosteroids: A boon or bane for COVID-19 patients? ⁶²	Sen S...Biswas G	36029810	2022
5	Efficacy and safety of COVID-19 vaccines. ⁶²	Grana C...Boutron I	36473651	2022
6	Functional status of recovered critical COVID-19 patients: An assessment of a convalescent cohort. ⁶²	Sousa L...Silva-Pinto A	36442914	2022
7	The Importance of Rehabilitation for Functional Recovery and Long-Term Outcomes for Recovery From Critical COVID-19 Illness. ⁶²	Rewa OG...Kho M	36394405	2022
8	Treatment of pregnant and early postpartum women with severe and critical COVID-19: experience at a tertiary center. ⁶²	Barbosa RN...Peret FJA	36461042	2022
9	Sleep and circadian health 6 months after critical COVID-19 disease. ⁶²	Targa ADS...Barbe F	36210340	2022
10	Functional status of recovered critical COVID-19 patients: An assessment of a convalescent cohort. ⁶²	Sousa L...Silva-Pinto A	35233125	2022
11	Management of Severe and Critical COVID-19 Infection with Immunotherapies. ⁶²	Athale J...Busch LM	36328635	2022
12	Association between heme oxygenase one and sepsis development in patients with moderate-to-critical COVID-19: a single-center, retrospective observational study. ⁶²	Chen HY...Su WL	36464717	2022
13	Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh. ⁶²	Hasan MJ...Huq SMR	35238257	2022
14	Performance analyses of prognostic scores in critical COVID-19 patients: think outside the numbers. ⁶²	Accordino S...Canetta C	35792754	2022
15	Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study. ⁶²	Martinez-Guerra BA...Ponce-de-Leon A	34839785	2022
16	Risk factors for severe and critical Covid-19 in pregnant women in a single center in Brazil. ⁶²	Tutiya C...Siaulys M	33535850	2022
17	Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. ⁶²	Hardt K...ENSEMBLE2 study group	36113538	2022
18	Supportive Care in Patients with Critical Coronavirus Disease 2019. ⁶²	Sweeney DA...Malhotra A	36328636	2022
19	Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. ⁶²	Fong Y...and the United States Government (USG)/CoVPN Biostatistics Team	36357712	2022
20	Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia. ⁶²	Nasrallah S...Gomez LM	33771091	2022
21	Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional study. ⁶²	Samanta J...Sharma A	35918490	2022
22	Challenges and difficulties faced in low- and middle-income countries during COVID-19. ⁶²	Moyazzem Hossain M...Rahman A	36405972	2022
23	Symptomatic versus asymptomatic COVID-19: does it impact placental vasculopathy? ⁶²	Ramey-Collier K...Dotters-Katz SK	35172668	2022
24	Predictors of severe and critical disease in pregnant women with SARS-CoV-2. ⁶²	Limaye MA...Penfield CA	34470122	2022
25	Autoantibodies against type I IFNs in patients with critical influenza pneumonia. ⁶²	Zhang Q...Casanova JL	36112363	2022
26	Genome-wide detection of human variants that disrupt intronic branchpoints. ⁶²	Zhang P...Casanova JL	36306325	2022
27	Associations between onychomycosis and COVID-19 clinical outcomes: a retrospective cohort study from a US metropolitan center. ⁶²	Rakita U...Silverberg JI	34773138	2022
28	Potential influence of COVID-19 and dexamethasone on the reproductive system: what we know and can expect. ⁶²	Chen F...Zhao Q	36345876	2022
29	Immune phenotypes that are associated with subsequent COVID-19 severity inferred from post-recovery samples. ⁶²	Liechti T...Roederer M	36433939	2022
30	Survival analysis of patients with COVID-19 admitted at six hospitals in Uganda in 2021: a cohort study. ⁶²	Muyinda A...Mukunya D	36380388	2022
31	Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study. ⁶²	Ben Fredj S...Ghannem H	36443699	2022
32	B-cell malignancies and COVID-19: a narrative review. ⁶²	Luque-Paz D...Lyon HEMINF Study Group	36336236	2022
33	Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. ⁶²	Cattaneo C...Pagano L	36428621	2022
34	Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients - A retrospective cohort study on 5392 patients from a tertiary centre. ⁶²	Bistrovic P...Lucijanic M	36471534	2022
35	COVID-19 related fears and adherence to infection control protocol amongst immunocompromised transplant recipients: A case study. ⁶²	Moazzam A...Mahmood Z	36415242	2022
36	IL-6, IL-10, sFas, granulysin and indicators of intestinal permeability as early biomarkers for a fatal outcome in COVID-19. ⁶²	Hernandez-Solis A...Wong-Baeza I	36209721	2022
37	The oldest unvaccinated Covid-19 survivors in South America. ⁶²	de Castro MV...Zatz M	36384671	2022
38	Early intubation and clinical outcomes in patients with severe COVID-19: a systematic review and meta-analysis. ⁶²	Lee HJ...Kim J	36329482	2022
39	Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients. ⁶²	Di Lorenzo A...Iannetta M	36359306	2022
40	Genetic variants and serum profiles of cytokines in COVID-19 severity. ⁶²	Alefishat E...UAE COVID-19 Collaborative Partnership	36378234	2022
41	Common mitochondrial haplogroups as modifiers of the onset-age for critical COVID-19. ⁶²	Vazquez-Coto D...Coto E	36115538	2022
42	Trends in survival during the pandemic in patients with critical COVID-19 receiving mechanical ventilation with or without ECMO: analysis of the Japanese national registry data. ⁶²	Ohshimo S...Japan ECMO Network	36380377	2022
43	Characteristics of lymphocyte subset alterations in COVID-19 patients with different levels of disease severity. ⁶²	Dai W...Xia X	36403042	2022
44	Kinetics of SuPAR hemoadsorption in critical COVID-19 patients on renal replacement therapy. ⁶²	Vicka V...Sipylaite J	36401202	2022
45	Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. ⁶²	John BV...Dahman B	36181987	2022
46	Health-related quality of life among persons with initial mild, moderate, and severe or critical COVID-19 at 1 and 12 months after infection: a prospective cohort study. ⁶²	Verveen A...RECoVERED Study Group	36324167	2022
47	What is the impact of previous cerebrovascular disease on critical COVID-19 patients' mortality? A prospective cohort study. ⁶²	Teixeira-Vaz A...Paiva JA	36037666	2022
48	Neurophysiological Findings in Critical COVID-19 Patients With Peripheral Nervous System Manifestations. ⁶²	Santiago-Perez S...Ruiz-Avila LA	36331159	2022
49	Use of convalescent plasma therapy in hospitalised adult patients with non-critical COVID-19: a focus on the elderly from Hungary. ⁶²	Kiss-Dala N...Valyi-Nagy I	36367599	2022
50	Characteristics of subarachnoid hemorrhage associated with COVID-19 infection: A systematic review and descriptive analysis. ⁶²	Lim MJR...Yeo TT	36442281	2022

Sources

Genes for Critical Covid-19

Genes related to Critical Covid-19 (0 elite genes):

(show all 27)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	8.61	DISEASES inferred ¹⁴ ¹⁴
2	ACE2	Angiotensin Converting Enzyme 2	Protein Coding	8.2	DISEASES inferred ¹⁴
3	IL6	Interleukin 6	Protein Coding	7.8	DISEASES inferred ¹⁴
4	CRP	C-Reactive Protein	Protein Coding	7.67	DISEASES inferred ¹⁴
5	TMPRSS2	Transmembrane Serine Protease 2	Protein Coding	7.16	DISEASES inferred ¹⁴
6	CXCL10	C-X-C Motif Chemokine Ligand 10	Protein Coding	6.89	DISEASES inferred ¹⁴
7	CD8A	CD8a Molecule	Protein Coding	6.82	DISEASES inferred ¹⁴
8	IL10	Interleukin 10	Protein Coding	6.81	DISEASES inferred ¹⁴
9	TNF	Tumor Necrosis Factor	Protein Coding	6.79	DISEASES inferred ¹⁴
10	CD4	CD4 Molecule	Protein Coding	6.73	DISEASES inferred ¹⁴
11	IL7	Interleukin 7	Protein Coding	6.73	DISEASES inferred ¹⁴
12	IFNB1	Interferon Beta 1	Protein Coding	6.72	DISEASES inferred ¹⁴
13	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	6.68	DISEASES inferred ¹⁴
14	CCL3	C-C Motif Chemokine Ligand 3	Protein Coding	6.68	DISEASES inferred ¹⁴
15	IL1B	Interleukin 1 Beta	Protein Coding	6.67	DISEASES inferred ¹⁴
16	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	6.61	DISEASES inferred ¹⁴
17	IFNA1	Interferon Alpha 1	Protein Coding	6.6	DISEASES inferred ¹⁴
18	IL2	Interleukin 2	Protein Coding	6.47	DISEASES inferred ¹⁴
19	SERPINA3	Serpin Family A Member 3	Protein Coding	6.33	DISEASES inferred ¹⁴ ¹⁴
20	CSF3	Colony Stimulating Factor 3	Protein Coding	6.26	DISEASES inferred ¹⁴
21	F3	Coagulation Factor III, Tissue Factor	Protein Coding	6.26	DISEASES inferred ¹⁴
22	ACE	Angiotensin I Converting Enzyme	Protein Coding	6.26	DISEASES inferred ¹⁴
23	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	6.17	DISEASES inferred ¹⁴
24	CSF2	Colony Stimulating Factor 2	Protein Coding	6.14	DISEASES inferred ¹⁴
25	F2	Coagulation Factor II, Thrombin	Protein Coding	6.14	DISEASES inferred ¹⁴
26	FURIN	Furin, Paired Basic Amino Acid Cleaving Enzyme	Protein Coding	6.07	DISEASES inferred ¹⁴
27	FCGR3B	Fc Gamma Receptor IIIb	Protein Coding	6.05	DISEASES inferred ¹⁴

Sources

Variations for Critical Covid-19

Sources

Expression for Critical Covid-19

Search GEO for disease gene expression data for Critical Covid-19.

Sources

Pathways for Critical Covid-19

Pathways related to Critical Covid-19 according to GeneCards Suite gene sharing:

(show top 50) (show all 76)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.98	CCL2 CCL3 CCR6 CD4 CD8A CRP
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.92	TNF IL7 IL6 IL2 IL1B IL10
3	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.74	CCL2 CCL3 CCR6 CD4 CSF3 CXCL10
4	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.65	CCL2 CCL3 CD4 CXCL8 IFNA1 IFNB1
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.53	TNF IL7 IL6 IL2 IL1B IL10
6	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.42	TNF IL7 IL6 IL2 IL1B IL10
7	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.36	CCL2 CCL3 CD4 CSF3 CXCL10 CXCL8
8	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	13.02	IL7 IL6 IL2 IFNB1 IFNA1 CSF3
9	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.99	CCL3 CXCL10 CXCL8 IFNA1 IFNB1 IL1B
10	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.94	CCL2 CCL3 CCR6 CD4 CXCL10 CXCL8
11	Malignant pleural mesothelioma ⁷⁴	12.81	IL6 IL1B IL10 CXCL10 CSF3 CCL2
12	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.78	TNF IL6 IL2 IL1B IL10 IFNB1
13	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.74	CCL2 CD4 IL10 IL1B IL2 IL6
14	NF-kappaB Signaling ³	12.72	TNF IL2 IL1B IL10 IFNA1 CXCL10
15	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.67	TNF IL6 IL1B IFNB1 IFNA1 CXCL8
16	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.58	CXCL10 CXCL8 IFNB1 IL1B IL6 TNF
17	Cytosolic sensors of pathogen-associated DNA ⁶⁶ Show member pathways Cytosolic DNA-sensing pathway ⁷⁴ DEx/H-box helicases activate type I IFN and inflammatory cytokines production ⁶⁶ IkBA variant leads to EDA-ID ⁶⁶ IRF3 mediated activation of type 1 IFN ⁶⁶ IRF3-mediated induction of type I IFN ⁶⁶ LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production ⁶⁶ Regulation by TREX1 ⁶⁶ Regulation of innate immune responses to cytosolic DNA ⁶⁶ RIP-mediated NFkB activation via ZBP1 ⁶⁶ Selenium micronutrient network ⁷⁴ STAT6-mediated induction of chemokines ⁶⁶ STING mediated induction of host immune responses ⁶⁶ ZBP1(DAI) mediated induction of type I IFNs ⁶⁶	12.52	IL6 IL1B IFNB1 IFNA1 CXCL10
18	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ⁶⁷ IL-17 signaling pathway ⁷⁴ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.44	TNF IL6 CXCL8 CXCL10 CSF3 CCL2
19	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.35	TNF IL6 IL1B CXCL8
20	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12.31	TNF IL6 IL1B IL10 CXCL8
21	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.31	TNF IL2 IL10 IFNB1 CD8A CD4
22	Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions ⁶⁵ Show member pathways Chemokine receptors bind chemokines ⁶⁶	12.2	CXCL8 CXCL10 CCR6 CCL3 CCL2
23	Neuroinflammation and glutamatergic signaling ⁷⁴	12.18	TNF IL6 IL1B IL10
24	Spinal cord injury ⁷⁴	12.18	CCL2 CXCL10 CXCL8 IL1B IL2 IL6
25	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	12.16	TNF IL7 IL6 IL2 IL10 CSF3
26	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	12.14	IL2 IL1B CD8A CD4 CCL3
27	Interleukin-4 and Interleukin-13 signaling ⁶⁶	12.13	TNF IL6 IL1B IL10 CXCL8 CCL2
28	Senescence and autophagy in cancer ⁷⁴	12.11	IL6 IL1B IFNB1 CXCL8 CCL3
29	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	12.09	TNF IL6 IL2 IL1B IL10 CD4
30	CCL18 signaling pathway ⁷⁴	12.07	IL6 IL10 CXCL8 CCR6 CCL3 CCL2
31	Allograft rejection ⁷⁴	12.05	TNF IL2 IL1B IL10 CXCL8
32	Burn wound healing ⁷⁴	11.94	TNF IL6 IL1B IFNB1 CXCL8 CCL2
33	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.91	TNF IL6 IL2 IL10 CRP
34	AP-1 transcription factor network ⁶¹	11.9	IL6 IL2 IL10 CXCL8 CCL2
35	Acute viral myocarditis ⁷⁴	11.89	IL6 IL2 IL10 CD4
36	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.89	IL6 IFNB1 CXCL8 CRP CD8A CD4
37	Th17 cell differentiation pathway ⁷⁴	11.85	CD4 IL1B IL2 IL6
38	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.85	CXCL8 IL1B IL2 IL6 TNF
39	Lung fibrosis ⁷⁴	11.85	TNF IL6 IL1B CXCL8 CSF3 CCL3
40	miRNAs involvement in the immune response in sepsis ⁷⁴	11.84	TNF IL6 IL10 CXCL8 CCL3
41	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.84	CD4 CD8A IFNB1 IL10 IL1B IL2
42	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.83	TNF IL1B IFNB1
43	Glucocorticoid receptor regulatory network ⁶¹	11.81	IL6 IL2 CXCL8
44	IL 10 signaling pathway ⁶⁷	11.81	TNF IL6 IL1B IL10
45	Innate Lymphoid Cells Differentiation ⁶⁵	11.81	CCL3 CCR6 CD4 CD8A IL10 IL1B
46	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.78	TNF IL6 IL2 IL10
47	Interleukin-6 family signaling ⁶⁶ Show member pathways IL-6-type cytokine receptor ligand interactions ⁶⁶ Immune response Oncostatin M signaling via JAK-Stat in human cells ²² Interleukin-6 signaling ⁶⁶	11.77	SERPINA3 IL6 CCL2
48	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.75	TNF IL2 CXCL8
49	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.71	TNF IL6 CXCL8 CCL2
50	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.71	TNF IL10 IFNB1 CXCL8 CCL3 CCL2

Sources

GO Terms for Critical Covid-19

Cellular components related to Critical Covid-19 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.16	ACE2 CCL2 CCL3 CRP CSF3 CXCL10
2	extracellular region	GO:0005576	9.88	ACE2 CCL2 CCL3 CD8A CRP CSF3

Biological processes related to Critical Covid-19 according to GeneCards Suite gene sharing:

(show all 40)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.47	CCL2 CCL3 CCR6 CD4 CSF3 CXCL10
2	positive regulation of gene expression	GO:0010628	10.42	CCL3 CRP CXCL8 IL1B IL6 IL7
3	cell-cell signaling	GO:0007267	10.35	IL7 IL2 IL1B CXCL10 CCL3
4	chemotaxis	GO:0006935	10.29	CCL2 CCL3 CCR6 CXCL10 CXCL8
5	defense response to Gram-positive bacterium	GO:0050830	10.28	TNF IL6 IL1B CRP
6	inflammatory response	GO:0006954	10.28	CCL2 CCL3 CRP CXCL10 CXCL8 IL1B
7	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.27	CSF3 IL10 IL1B IL6 TNF
8	positive regulation of inflammatory response	GO:0050729	10.25	TNF IL2 IL1B CCL3
9	cellular response to virus	GO:0098586	10.22	IL6 IFNB1 IFNA1 CXCL10
10	cellular response to organic cyclic compound	GO:0071407	10.19	TNF IL1B CCL3 CCL2
11	protein kinase B signaling	GO:0043491	10.18	TNF IL1B CCL3 CCL2
12	B cell proliferation	GO:0042100	10.16	IL7 IL10 IFNB1 IFNA1
13	acute-phase response	GO:0006953	10.15	SERPINA3 IL6 CRP
14	negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	GO:2001240	10.14	TNF IL7 IL1B
15	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.14	TNF IL6 IL10
16	calcium-mediated signaling	GO:0019722	10.13	CCL3 CCR6 CD4 CXCL8 TNF
17	liver regeneration	GO:0097421	10.12	IL10 IL6 TNF
18	positive regulation of immunoglobulin production	GO:0002639	10.11	IL6 IL2 IL10
19	negative regulation of neurogenesis	GO:0050768	10.1	IL1B IL6 TNF
20	neutrophil chemotaxis	GO:0030593	10.1	IL1B CXCL8 CXCL10 CCL3 CCL2
21	cytokine-mediated signaling pathway	GO:0019221	10.1	IL7 IL6 IL1B IFNB1 IFNA1 CSF3
22	positive regulation of chemokine production	GO:0032722	10.09	IL1B IL6 IL7 TNF
23	positive regulation of glial cell proliferation	GO:0060252	10.08	TNF IL6 IL1B
24	positive regulation of heterotypic cell-cell adhesion	GO:0034116	10.08	TNF IL1B IL10
25	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.08	TNF IL1B CCL3 CCL2
26	chemokine-mediated signaling pathway	GO:0070098	10.07	CCL2 CCL3 CCR6 CXCL10 CXCL8
27	cellular response to lipopolysaccharide	GO:0071222	10.03	CCL2 CSF3 CXCL10 CXCL8 IL10 IL1B
28	positive regulation of neuroinflammatory response	GO:0150078	10	TNF IL6 IL1B
29	negative regulation of lipid storage	GO:0010888	9.99	TNF IL6 CRP
30	negative regulation of cytokine production involved in immune response	GO:0002719	9.98	TNF IL10
31	positive regulation of fever generation	GO:0031622	9.98	TNF IL1B
32	cellular response to interleukin-17	GO:0097398	9.97	IL1B CXCL10
33	sequestering of triglyceride	GO:0030730	9.96	IL1B TNF
34	positive regulation of plasma cell differentiation	GO:1900100	9.94	IL2 IL10
35	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.94	TNF IL1B
36	defense response	GO:0006952	9.93	TNF IFNB1 IFNA1 CXCL8 CXCL10
37	vascular endothelial growth factor production	GO:0010573	9.93	TNF IL6 IL1B
38	chronic inflammatory response to antigenic stimulus	GO:0002439	9.92	TNF IL10
39	humoral immune response	GO:0006959	9.8	CCL2 CCR6 IFNA1 IFNB1 IL6 IL7
40	immune response	GO:0006955	9.62	TNF IL7 IL6 IL2 IL1B IL10

Molecular functions related to Critical Covid-19 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	growth factor activity	GO:0008083	9.85	IL7 IL6 IL2 IL10 CSF3
2	cytokine activity	GO:0005125	9.66	CCL2 CCL3 CSF3 CXCL10 CXCL8 IFNA1
3	cytokine receptor binding	GO:0005126	9.56	IL7 IFNB1 IFNA1
4	chemokine activity	GO:0008009	9.56	CXCL8 CXCL10 CCL3 CCL2